Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 2;14(15):3762.
doi: 10.3390/cancers14153762.

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices

Inne Nauwelaers  1 , Nele Laudus  1 , Dieter Peeters  2   3 , Balazs Acs  4   5 , Carsten Denkert  6 , Stefan Michiels  7   8 , Hugo Horlings  9   10 , Kalliopi P Siziopikou  11 , Scott Ely  12 , Dimitrios Zardavas  13 , Roberts Mustimbo  12 , John Bartlett  14 , Giuseppe Floris  15   16 , Johan Hartman  4   5 , Carolien H M van Deurzen  17 , Dorien Ceusters  1 , Els Dequeker  1 , Roberto Salgado  18   19
Affiliations
Editorial

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices

Inne Nauwelaers et al. Cancers (Basel). .

Abstract

Increasing data suggests that an intact immune system is required for improvedoutcomes in patients with Human Epidermal Growth Factor Receptor 2 (HER2+) and Triple Negative Breast Cancer (TNBC) [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
After registration, through www.tilsinbreastcancer.org (accessed on 15 July 2021), a training module will be available for PD-L1 and TILs. Next, a pilot EQA module will be available to assess the current practices and competences of pathologists to score TILs. Finally, individual feedback will be offered to each participant separately.
See this image and copyright information in PMC

References

    1. Denkert C., Von Minckwitz G., Darb-Esfahani S., Lederer B., Heppner B.I., Weber K.E., Budczies J., Huober J., Klauschen F., Furlanetto J., et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50. doi: 10.1016/S1470-2045(17)30904-X. - DOI - PubMed
    1. Loi S., Adams S., Schmid P., Cortés J., Cescon D.W., Winer E.P., Toppmeyer D.L., Rugo H.S., De Laurentiis M., Nanda R., et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann. Oncol. 2017;28:v608. doi: 10.1093/annonc/mdx440.005. - DOI
    1. Amgad M., Stovgaard E.S., Balslev E., Thagaard J., Chen W., Dudgeon S., Sharma A., Kerner J.K., Denkert C., Yuan Y., et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. npj Breast Cancer. 2020;6:16. doi: 10.1038/s41523-020-0154-2. - DOI - PMC - PubMed
    1. Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., Wienert S., Van den Eynden G., Baehner F.L., Penault-Llorca F., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015;26:259–271. doi: 10.1093/annonc/mdu450. - DOI - PMC - PubMed
    1. Denkert C., Wienert S., Poterie A., Loibl S., Budczies J., Badve S., Bago-Horvath Z., Bane A., Bedri S., Brock J., et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. Mod. Pathol. 2016;29:1155–1164. doi: 10.1038/modpathol.2016.109. - DOI - PubMed

Publication types